Adaptimmune Therapeutics PLC financial statements
Adaptimmune Therapeutics PLC's income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.
FY2024
| Revenue | USD 178.03M | 10-K |
| Net income | −USD 70.81M | 10-K |
| Cash and equivalents | USD 91.14M | 10-Q |
| Total debt | USD 54.28M | 10-K |
Adaptimmune Therapeutics PLC financials on 6ix · Adaptimmune Therapeutics PLC on 6ix